The first EU Joint Clinical Assessment (JCA) has now been published, providing the first practical insight into how the EU HTA Regulation is being applied in practice.
In this on-demand session, Remap’s HTA and market access experts examine the assessment of tovorafenib as a case study, exploring what the first JCA reveals about evidence expectations, uncertainty management, PICO challenges, and the implications for future submissions.
Rather than focusing on the theory of EU HTA, the discussion centres on the strategic lessons manufacturers can take forward as they prepare for upcoming Joint Clinical Assessments.
Access The Recording
What the session covers:
- Key observations from the first published EU Joint Clinical Assessment
- What happened in practice and how the process compared with expectations
- Where evidence challenges emerged and how uncertainty was addressed within the assessment
- Strategic implications for PICO development, evidence planning, and submission readiness
- Practical considerations for manufacturers navigating increasingly complex clinical pathways and evidence-generation constraints
Continue the discussion with our webinar Q&A follow-up document, featuring expert responses to attendee questions on PICO development, evidence uncertainty, and HTA strategy.